BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines
Academic Article
Overview
MeSH Major
Carcinoma
Drug Resistance, Neoplasm
Mitogen-Activated Protein Kinase Kinases
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Thyroid Neoplasms
abstract
Thyroid cancers with BRAF mutation are preferentially sensitive to MEK inhibitors, whereas tumors with other MEK-ERK effector pathway gene mutations have variable responses, either because they are only partially dependent on ERK and/or because feedback responses elicit partial refractoriness to MEK inhibition.
